The Diagnostic Performance of Fecal Immunochemical Tests for Detecting Advanced Neoplasia at Surveillance Colonoscopy
Clinical Gastroenterology and Hepatology · 2024
DOI: 10.1016/j.cgh.2023.09.016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2024. Verfasst von Grace Berwald und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, College of Medicine and Public Health, Flinders University, Bedford Park, South Australia, Australia. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Adenoma. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Flinders University.
Abstract (Originalsprache)
BACKGROUND & AIMS: An increasing burden on health care resources has resulted in a backlog of individuals requiring colonoscopy, with delays in surveillance possibly detrimental for individuals at increased risk of colorectal cancer (CRC). This study investigated the use of a 2-sample fecal immunochemical test (FIT) to establish those most likely to have advanced neoplasia (AN) and in need of prioritized surveillance colonoscopy. METHODS: This was a prospective study conducted in the tertiary care setting. Participants completed a 2-sample FIT (OC-Sensor, Eiken Chemical Company) within 90 days of surveillance colonoscopy. The sensitivity of FIT for detection of AN (CRC or advanced adenoma) in moderate- and high-risk individuals was determined at fecal hemoglobin thresholds between 2 and 80 μg/g feces. RESULTS: A total of 766 patients were included (median age, 66.1 years [interquartile range, 58.1-72.9]; 49.9% male), with AN detected in 8.6% (66/766, including 5 CRC). For moderate-risk individuals (with prior history of adenoma or a significant family history of CRC), sensitivity of FIT for AN ranged from 73.5% at 2 μg/g feces, to 10.2% at 80 μg/g feces. For high-risk conditions (confirmed/suspected genetic syndromes or prior CRC), sensitivity of FIT was similar, ranging from 70.6% at the lowest positivity threshold of 2 μg/g feces, to 11.8% at 80 μg/g feces. Independent variables in the whole cohort for association with detection of AN at surveillance colonoscopy were age (odds ratio, 1.03; 95% confidence interval, 1.00-1.06) and FIT hemoglobin result ≥10 μg/g feces (odds ratio, 1.81; 95% confidence interval, 1.04-3.16). CONCLUSIONS: The use of FIT before surveillance colonoscopy provides clinicians with insights into the risk of AN. This raises the possibility of a method to triage individuals, facilitating the more efficient management of endoscopic resources.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, College of Medicine and Public Health, Flinders University, Bedford Park, South Australia, Australia.
- Cancer Research, Flinders Health and Medical Research Institute, Bedford Park, South Australia, Australia.
- Cancer Research, Flinders Health and Medical Research Institute, Bedford Park, South Australia, Australia; Department of Gastroenterology and Hepatology, Flinders Medical Centre, Southern Adelaide Local Health Network,…
Förderung
- Flinders University
Zitieren
APA
Berwald, G., Young, G. P., Cock, C., Bampton, P., Fraser, R., & Symonds, E. L. (2024). The Diagnostic Performance of Fecal Immunochemical Tests for Detecting Advanced Neoplasia at Surveillance Colonoscopy. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2023.09.016
Vancouver
Berwald G, Young GP, Cock C, Bampton P, Fraser R, Symonds EL. The Diagnostic Performance of Fecal Immunochemical Tests for Detecting Advanced Neoplasia at Surveillance Colonoscopy. Clinical Gastroenterology and Hepatology. 2024. doi:10.1016/j.cgh.2023.09.016
BibTeX
@article{Berwald2024,
author = {Berwald, Grace and Young, Graeme P and Cock, Charles and Bampton, Peter and Fraser, Robert and Symonds, Erin L},
title = {The Diagnostic Performance of Fecal Immunochemical Tests for Detecting Advanced Neoplasia at Surveillance Colonoscopy},
journal = {Clinical Gastroenterology and Hepatology},
year = {2024},
doi = {10.1016/j.cgh.2023.09.016}
}
EUVIMED